Abstract
A historically controlled phase II study was undertaken to investigate the efficacy and toxicity of a postoperative treatment consisting of high-dose continuous tamoxifen, carboplatin and radiotherapy in patients with newly diagnosed glioblastoma. Between 1995 and 1998, 50 patients with newly diagnosed glioblastomas underwent surgery and were subsequently treated with 200 mg day−1 tamoxifen continuously, 3 cycles of carboplatin (300 mg m−2), and radiotherapy. Survival data for a historical control group were calculated from respective prognostic indices and were obtained from studies with comparable patient populations treated with operation and radiotherapy only. In our study, the median time to tumor progression was 30 weeks and the median survival time (MST) 55 weeks (95% confidence interval: 46–63 weeks). The MST of the control group (48 weeks) showed to be within this interval. In addition to already known prognostic factors in malignant gliomas (age, Karnofsky performance score, extent of tumor resection), the gender (females lived longer than males, p = 0.0025) showed to influence survival. Serious side effects (thrombosis, pulmonary embolism) occurred in 6 patients. A high incidence of multifocal tumor recurrences (33%), which might be related to study-treatment, was observed. In conclusion, the combined therapy failed to demonstrate a higher efficacy than standard treatment for glioblastoma patients.
Similar content being viewed by others
References
Legha SS: Tamoxifen in the treatment of breast cancer. Ann Intern Med 109: 219-228, 1988
Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick Jr FT: Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res 50: 7134-7138, 1990
Stojkovic RR, Jovancevic M, Santel DJ, Grcevic N, Gamulin S: Sex steroid receptors in intracranial tumors. Cancer 65: 1968-1970, 1990
Baltuch GH, Couldwell WT, Villemure JG, Yong VW: Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen. Neurosurgery 33: 495-501, 1993
Puchner MJA, Giese A: Tamoxifen-resistant glioma-cell-subpopulations are characterized by increased migration and proliferation. Int J Cancer 86: 468-473, 2000
Couldwell WT, Antel JP, Yong VW: Protein kinase C activity correlates with the growth rate of malignant gliomas: part II: effects of glioma mitogens and modulators of protein kinase C. Neurosurgery 31: 717-724, 1992
Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258: 607-614, 1992
Couldwell WT, Weiss MH, DeGiorgio CM, Weiner LP, Hinton DR, Ehresmann GR, Conti PS, Apuzzo MLJ: Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 32: 485-490, 1993
Vertosick Jr FT, Selker RG, Pollack IF, Arena V: The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of 'failed' patients. Neurosurgery 30: 897-903, 1992
McClay EF, McClay MET: Tamoxifen: is it useful in the treatment of patients with metastatic melanoma? J Clin Oncol 12: 617-626, 1994
Pass HW, Temeck BK, Kranda K, Steinberg SM, Pass HI: A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction. Ann Surg Oncol 2: 214-220, 1995
Hoff von DD: Whither Carboplatin?-A replacement for or an alternative to Cisplatin? J Clin Oncol 5:169-171, 1987
Cristante L, Siepmann G, Westphal M, Hagel C, Herrmann HD: Superselective intraarterial cisplatin application for recurrent malignant gliomas. Reg Cancer Treat 4: 188-194, 1992
Donsson AM, Weil MD, Foreman NK: Tamoxifen radiosensitization in human glioblastoma cell lines. J Neurosurg 90: 533-536, 1999
EORTC Brain Tumor Group: Cisplatin does not enhance the effect of radiation therapy in malignant gliomas. Eur J Cancer 27: 568-571, 1991
Lunardi P, Farah JO, Mastronardi F, Puzzilli F, Lo Bianco FM: Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study. Acta Neurochir (Wien) 138: 215-220, 1996
Zhang W, Yamada H, Sakai N, Niikawa S, Nozawa Y: Enhancement of radiosensitivity by tamoxifen in C6 glioma cells. Neurosurgery 31: 725-730, 1992
Irish WD, McDonald DR, Cairncross JG: Measuring bias in uncontrolled brain tumor trials-to randomize or not to randomize? Can J Neurol Sci 24: 307-312, 1997
World Health Organization: Handbook for reporting results of cancer treatment. WHO offset publication no.48: Geneva, 1979
Curran Jr WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, Nelson DF: Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 85: 704-710, 1993
Medical Research Council: Prognostic factors for high-grade malignant glioma: development of a prognostic index. A report of the Medical Research Council Brain Tumour Working Party. J Neuro-Oncol 9: 47-55, 1990
Barker II FG, Prados MD, Chang SM, Gutin PH, Lamborn KR, Larson DA, Malec MK, McDermott MW, Sneed PK, Wara WM, Wilson CB: Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg 84: 442-448, 1996
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
Cox DR: Regression models and life tables. J R Stat Soc (B) 34: 187-229, 1972
Albert FK, Forsting M, Sartor K, Adams HP, Kunze S: Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34: 45-61, 1994
Devaux BC, O'FaIIon JR, Kelly PJ: Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 78: 767-775, 1993
Couldwell WT, Hinton DR, Surnock M, DeGiorgio CM, Weiner LP, Apuzzo MLJ, Masri L, Law RE, Weiss MH: Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 2: 619-622, 1996
Brandes AA, Ermani M, Turazzi S, Scelzi E, Berti F, Amista P, Rotilio A, Licata C, Fiorentino MV: Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. J Clin Oncol 17: 645-650, 1999
Chamberlain MC, Kormanik PA: Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch Neurol 56: 703-708, 1999
Chang SM, Barker II FG, Huhn SL, Nicholas MK, Page M, Rabbitt J, Prados MD: High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma. J Neuro-Oncol 37 169-176, 1998.
Mastronardi L, Puzzilli F, Couldwell WT, Farah JO, Lunardi P: Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients. J Neuro-Oncol 38: 59-68, 1998
Arita N, Taneda M, Hayakawa T: Leptomeningeal dissemination of malignaht gliomas. Incidence, diagnosis and outcome. Acta Neurochir (Wien) 126: 84-92, 1994.
Barker II FG, Chang SM, Gutin PH, Malec MK, McDermott MW, Prados MD, Wilson CB: Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42: 709-723, 1998
Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 30: 907-911, 1980
Preul MC, Caramanos Z, Villemure JG, Shenouda G, LeBlanc R, Langleben A, Arnold DL: Using proton magnetic resonance spectroscopic imaging to predict in vivo the response to recurrent malignant gliomas of tamoxifen chemotherapy. Neurosurgery 46: 306-318, 2000
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Puchner, M.J., Herrmann, HD., Berger, J. et al. Surgery, Tamoxifen, Carboplatin, and Radiotherapy in the Treatment of Newly Diagnosed Glioblastoma Patients. J Neurooncol 49, 147–155 (2000). https://doi.org/10.1023/A:1026533016912
Issue Date:
DOI: https://doi.org/10.1023/A:1026533016912